People
Seven biopharma companies are under new leadership. This week’s Movers & Shakers highlights these new chief executive officers who aim to guide their companies into the future.
Beyond the usual challenge of delivering high-quality data that answers meaningful questions, PepGen’s Michelle Mellion is dedicated to “incorporating the patient’s voice into everything we do.”
Biopharma and life science companies added changes to their leadership teams this week, with Cara Therapeutics, SOTIO Biotech, Agenus, and more filling several C-suite positions.
Bayer CEO Werner Baumann may be on the way out. For the past several years, Baumann has been in the sites of angry shareholders but has evaded an ouster. That soon may be over.
President Joe Biden tapped Ginkgo Bioworks veteran Renee Wegrzyn to helm the recently-established Advanced Research Projects Agency for Health (ARPA-H).
Homology Medicines and MiMedx both posted new CEOs. Other C-suite positions, including CFOs and CMOs were also filled this week.
Biopharma and life sciences companies, such as Seraxis, Verily and Vaxart, tap new members to bolster their leadership teams in roles like CMO, CTO, CCO, and more.
A High Court judge in London granted AstraZeneca an injunction, temporarily blocking a former executive from joining rival pharma GSK.
Fiona H. Marshall has been tapped as Novartis Institutes for BioMedical Research president after Jay Bradner’s exit, while Tim Demuth will succeed Malte Peters for MorphoSys.
Despite being the largest minority group in the United States, the contributions of disabled people are remarkedly underreported in the life sciences industry.
PRESS RELEASES